Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACHN is in the long-term down -81% below S&P in 8 years.
Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
|Shares Outstanding||EPS||-0.47||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-9|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-25.83%||ROE||-27.14%||ROI|
|Current Ratio||19.64||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||138.96 M||Cash From Investing Activities||-148.58 M||Cash From Operating Activities||-17.32 M||Gross Profit|
|Net Profit||-19.26 M||Operating Profit||-19.4 M||Total Assets||279.42 M||Total Current Assets||255.58 M|
|Total Current Liabilities||13.01 M||Total Debt||610 K||Total Liabilities||13.41 M||Total Revenue|
|High 52 week||5.15||Low 52 week||2.65||Last close||3.1||Last change||1.31%|
|RSI||20.21||Average true range||0.12||Beta||0.8||Volume||2.41 M|
|Simple moving average 20 days||-9.36%||Simple moving average 50 days||-12.63%||Simple moving average 200 days||-13.92%|
|Performance Week||-1.27%||Performance Month||-10.92%||Performance Quart||-26.37%||Performance Half||6.9%|
|Performance Year||-26.01%||Performance Year-to-date||7.64%||Volatility daily||2.03%||Volatility weekly||4.55%|
|Volatility monthly||9.32%||Volatility yearly||32.3%||Relative Volume||236.65%||Average Volume||1.22 M|
|New High||New Low|
2020-01-29 14:04:44 | $930 million sale of Blue Bell biopharma firm finalized
2020-01-27 10:25:03 | Will Soliris, Ultomiris Drive Alexion's ALXN Q4 Earnings?
2020-01-08 07:48:12 | Apellis' APLS PNH Drug Betters Alexion's Soliris in Study
2020-01-02 09:49:02 | 4 Reasons Why Investors Should Buy Alexion ALXN in 2020
2019-12-20 11:46:51 | Achillion shareholders approve proposed $930M sale of company
2019-12-19 09:24:16 | Achillion Shareholders Approve Agreement to be Acquired by Alexion
2019-12-09 19:08:22 | Did Hedge Funds Drop The Ball On Achillion Pharmaceuticals, Inc. ACHN ?
2019-12-09 10:00:10 | Achillion Reports Positive Data from Phase 2 Study of Danicopan ACH-4471 in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
2019-12-07 11:31:04 | Why Is Achillion ACHN Down 2.8% Since Last Earnings Report?
2019-11-29 23:30:10 | Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.
2019-11-29 11:49:29 | 8 Stocks Paul Tudor Jones Continues To Buy
2019-11-27 12:15:05 | 5 Stocks That Pushed Russell 2000 ETF Higher
2019-11-20 09:50:02 | Achillion's ACHN Danicopan Gets EMA's PRIME Tag for PNH
2019-11-14 09:58:02 | Alexion ALXN Up 10 % YTD on Soliris & Ultomiris Strength
2019-11-11 07:30:00 | Achillion Announces Clearance of Investigational New Drug Application for ACH-5228
2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks
2019-11-07 07:30:00 | Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-11-06 14:36:44 | Here is What Hedge Funds Think About Achillion Pharmaceuticals, Inc. ACHN
2019-11-04 14:55:00 | Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.
2019-10-30 10:43:57 | Healthcare ETFs Win in October: Here's Why
2019-10-24 11:26:00 | ACHILLION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Achillion Pharmaceuticals, Inc. - ACHN
2019-10-23 11:26:03 | Alexion ALXN Beats on Q3 Earnings, Lifts 2019 Guidance
2019-10-23 10:10:02 | Biotech ETFs Surge on a Flurry of Positive News
2019-10-23 09:45:01 | Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
2019-10-21 09:33:01 | Alexion Gets FDA Approval for Label Expansion of Ultomiris
2019-10-19 10:30:00 | INVESTOR ALERT: Monteverde & Associates PC Is Investingating The Merger
2019-10-18 16:50:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.
2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?